S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (NCT00551460)
Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibody-drug conjugates or ADCs, such as gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread.
Gemtuzumab ozogamicin may also stop the growth of promyelocytic leukemia by blocking blood flow to the cancer. Giving gemtuzumab ozogamicin together with combination chemotherapy may be more effective in treating promyelocytic leukemia.
This phase II trial is studying how well giving gemtuzumab together with combination chemotherapy works in treating patients with previously untreated promyelocytic leukemia
- Condition: Leukemia
- Phase: II
- Estimated Enrollment: 70
- Start: November 2007
- Estimated Primary Completion: June 2016
- Last verified: March 2015
Last Editorial review: July 22, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.